Clinical Trial Update: Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma [Phase 2]

View source ↗

Summary

An update on the completed Phase 2 study of SGN-30, an anti-CD30 monoclonal antibody, in patients with refractory or recurrent anaplastic large cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma

Drugs mentioned

• SGN-30 (brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Anaplastic Large-Cell Lymphoma | Phase 2 | Status: COMPLETED